Venetoclax ex vivo response matches clinical response in 2 T-PLL patients. (A) Heatmap of viability measurements for 106 compounds in 4 concentrations in patient 1. The 4 concentrations used for each compound are depicted in supplemental Table 1. Venetoclax clusters on top. (B) Clinical response of T-PLL patient 1. (C) Heatmap of viability measurements for 106 compounds in 4 concentrations in patient 2. Venetoclax clusters on top. (D) Clinical response of T-PLL patient 2. (E) Dose-response curve of venetoclax of patients 1 and 2 before and after venetoclax treatment as well as CLL and AML samples. Concentrations ranging from 0.7 nM to 13 µM in threefold dilutions at 10 concentration points with 8 replicates each. Samples used for western blot in panel F are marked in red. (F) Western blot for BCL-2, BCL-XL, and MCL-1 of samples used in panel E. Total protein stain was performed with Ponceau S. Antibodies used were: BCL-2 (BD Biosciences), MCL-1 (Cell Signaling Technology), BCL-XL (Cell Signaling Technology), horseradish peroxidase (HRP)-conjugated donkey anti-mouse, and HRP-conjugated donkey anti-rabbit (Jackson ImmunoResearch).